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Background: The significant malaria burden in Africa has often eclipsed other febrile illnesses. Burkina Faso’s first
dengue epidemic occurred in 1925 and the most recent in 2013. Yet there is still very little known about dengue
prevalence, its vector proliferation, and its poverty and equity impacts.
Methods: An exploratory cross-sectional survey was performed from December 2013 to January 2014. Six primary
healthcare centers in Ouagadougou were selected based on previously reported presence of Flavivirus. All patients
consulting with fever or having had fever within the previous week and with a negative rapid diagnostic test (RDT)
for malaria were invited to participate. Sociodemographic data, healthcare use and expenses, mobility, health-related
status, and vector control practices were captured using a questionnaire. Blood samples of every eligible subject were
obtained through finger pricks during the survey for dengue RDT using SD BIOLINE Dengue Duo (NS1Ag and IgG/IgM)®
and to obtain blood spots for reverse transcription polymerase chain reaction (RT-PCR) analysis. In a sample of randomly
selected yards and those of patients, potential Aedes breeding sites were found and described. Larvae were collected
and brought to the laboratory to monitor the emergence of adults and identify the species.
Results: Of the 379 subjects, 8.7 % (33/379) had positive RDTs for dengue. Following the 2009 WHO classification,
38.3 % (145/379) had presumptive, probable, or confirmed dengue, based on either clinical symptoms or laboratory
testing. Of 60 samples tested by RT-PCR (33 from the positive tests and 27 from the subsample of negatives), 15 were
positive. The serotypes observed were DENV2, DENV3, and DENV4. Odds of dengue infection in 15-to-20-year-olds and
persons over 50 years were 4.0 (CI 95 %: 1.0–15.6) and 7.7 (CI 95 %: 1.6–37.1) times higher, respectively, than in children
under five. Average total spending for a dengue episode was 13 771 FCFA [1 300–67 300 FCFA] (1$US = 478 FCFA). On
average, 2.6 breeding sites were found per yard. Potential Aedes breeding sites were found near 71.4 % (21/28) of
patients, but no adult Aedes were found. The most frequently identified potential breeding sites were water storage
containers (45.2 %). Most specimens collected in yards were Culex (97.9 %).
Conclusions: The scientific community, public health authorities, and health workers should consider dengue as a
possible cause of febrile illness in Burkina Faso.
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Background
West African countries are carrying an enormous mal-
aria burden [1]. In Burkina Faso alone, the number of
malaria deaths is estimated at nearly 40 000 annually [2].
Several interventions have been put in place to reduce
that burden, and the results thus far have been positive,
with malaria on the decline since 2004 [2, 3]. Malaria
control is likely to improve exponentially over the coming
years due to three key interventions: 1) mass distributions
of long-lasting insecticidal nets (LLINs) in 2010 and 2013
[4]; 2) the use of malaria rapid diagnostic testing (RDT) in
all public healthcare centers since 2012; and 3) malaria
treatment in the form of Artemisinin-based combination
therapy (ACT) administered routinely by community
health workers (CHWs) since 2010 [5]. As such, the pro-
portion of febrile under-five children given antimalarials
rose from 35 % in 2010 to 49.2 % in 2014, and even up to
66.1 % in certain regions [6–8].
The undeniable magnitude of the malaria burden un-
doubtedly contributes to the lesser concern shown by
decision-makers, health workers, and researchers for
other febrile illnesses [9]. Some have stressed the need
for “deconstructing ‘malaria’ in West Africa” [10]. Health
workers are still trained with the idea that all fever is
synonymous with malaria. Yet fever, a major driver for
healthcare center consultations, can be symptomatic of
several illnesses, including not only malaria, but also
diarrhea, typhoid, or even dengue [11, 12]. Indeed, the
World Health Organization (WHO) worries that “den-
gue continues to be underreported in Africa owing to a
lack of awareness among health-care providers, the pres-
ence of other febrile illnesses (especially malaria)…” [13].
In Africa, there is growing interest in fever not associ-
ated with malaria, as clearly shown in recent studies in
Tanzania and Senegal [12, 14]. However, dengue is a fe-
brile illness that resembles several others, including mal-
aria [15, 16]. Even though the global impact of dengue is
immense, there is still very little known about its preva-
lence and burden in Africa [15, 17, 18].
The first dengue epidemic in Burkina Faso occurred in
1925 [17]. Later, a significant number of cases were seen
in the 1980s [17, 19] and identified as DENV2 [19, 20].
In the 2000s, DENV1 was found among travellers return-
ing from Burkina Faso [21]. In fact, Burkina Faso is one of
the 34 African countries in which dengue cases have been
reported since the 2000s [15, 17, 22]. A 2003 study of 191
blood donors and 492 pregnant women in two districts,
one rural (Nouna) and one urban (Ouagadougou), showed
that between 26 and 39 % of those surveyed had been incontact with the dengue virus [23]. Another study, con-
ducted in 2004 with 3 000 children in Ouagadougou,
found that 22 % of them had been in contact with a virus
of the Flavivirus family, to which the dengue virus belongs
[24]. More recently, an epidemic broke out in 2013, espe-
cially in the capital [25, 26]. Moreover, DENV3 was identi-
fied in a European patient who had travelled in Burkina
Faso in 2013 [27] and in a sample of 43 patients of two
health facilities in the capital in 2013 [25].
In Burkina Faso, Aedes aegypti is the primary known
dengue vector in urban areas [20]. However, whereas
knowledge about vector species is essential for the devel-
opment of strategies to control a disease like dengue, the
fact is that our knowledge is old and not very up-to-
date. Yet rampant population growth, poorly planned
urbanization, and the circulation of people and goods
are all factors that can encourage its emergence and the
arrival of new vectors such as Aedes albopictus, which is
known to be very invasive, based on what is currently
being observed in central Africa [28, 29].
So, we have only very limited knowledge at this time
about the dengue virus in Africa in general [11] and in
Burkina Faso in particular [9]. Before 2013, dengue was
not taken into account in health statistics and was not
among the diseases requiring notification in the surveil-
lance system [30]. Then, in 2013, the African Union
called for implementation of dengue control interven-
tions. However, more effective development of dengue
control strategies requires—beyond international best
practices [31] and WHO recommendations [32]— local
evidence to support the country’s decision-makers. We
therefore conducted a cross-sectional study in the capital
to gain a better understanding of the epidemiological, clin-
ical, entomological, and public health situations with re-
gard to dengue and its vector in acute febrile non-malaria
cases.Methods
Design and population
An exploratory cross-sectional survey was conducted be-
tween December 9, 2013, and January 4, 2014. Five sectors
and six corresponding primary healthcare centers (CSPSs)
in Ouagadougou, the capital of Burkina Faso (Fig. 1), were
selected based on previously reported presence of Flavivirus
[24]: CSPS 3 and 12 (Dapoya), 8 (Gounghin), 18 (Pissy), 25
(Somgande), and 28 (Dassasgho).Selection criteria
All patients consulting with fever (axillary tempe-
rature ≥ 38 °C) at the moment of the survey or with
history of fever within the previous week and with a
negative rapid diagnostic test (RDT) for malaria were
invited to participate in the study.
Fig. 1 Study map
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Sociodemographic data, presence and history of fever,
healthcare use and expenses, mobility (local and inter-
national), health-related status (including current symp-
toms), and information about vector control practices
were obtained through the administration of a struc-
tured questionnaire by trained nurses. Blood samples of
every eligible subject (n = 379) were obtained through
finger pricks during the survey to perform a dengue
rapid diagnostic test (NS1Ag and IgG/IgM) and to ob-
tain blood spots for RT-PCR analysis.Rapid diagnostic testing
Following aseptic preparation of the subject, finger
prick blood samples were obtained and introduced into
each of the two cassettes of the commercially available
kit SD BIOLINE Dengue Duo (Standard Diagnostics,
Seoul, South Korea)® followed by the addition of the
assay diluents. Results were read 15–20 min after per-
forming each test; in cases of invalid results, another
procedure was conducted with a new cassette. All pro-
cedures were conducted according to the manufac-
turer’s indications.RT-PCR analysis
Finger prick blood samples were collected in filter paper
(Whatman® 3MM) from every subject with a positive
dengue RDT result. Additionally, a sample was collected
from every tenth subject with a negative result to see
whether it was possible to identify virus presence in pa-
tients with negative RDT (i.e., false negative). These filter
papers, when dried, were stored individually in a Ziploc®
bag in a dry cool place between 4 and 15 °C and subse-
quently used for RT-PCR analysis at the microbiology la-
boratory at the Universidad del Valle (Cali, Colombia).
The DENV RNA was detected by a conventional DENV-
1–4 nested RT-PCR protocol. The viral RNA was ex-
tracted from the filter-paper eluted blood samples with
the QIAamp® Viral RNA kit (QIAGEN, Germantown,
MD). The cDNA was prepared by reverse transcription
of RNA using reverse transcriptase avian myeloblastosis
virus (Promega, Madison, WI) and an antisense primer,
followed by two rounds of nested-PCR. The final PCR
products were compared with the DNA band size of the
assay positive controls (CDC Reference DENV-1–4
strains) [33]. To confirm the dengue specificity of the
PCR products amplified from the samples, the PCR
amplicons of the correct size were further sequenced by
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Cycle Sequencing protocol (Macrogen Inc., South Korea).
Nucleotide sequences of the PCR products amplified by
RT-PCR corresponded to cDNA sequences of dengue
virus serotypes 2, 3 and 4.
Data analysis
We used the 2009 WHO dengue classification to iden-
tify dengue cases [34]. Based on the presence or
absence of diagnostic confirmation, we identified: 1)
presumptive cases (clinical symptoms without labora-
tory investigation); 2) probable cases (positive IgM and/
or IgG); and 3) confirmed cases (positive AgNS1 and/or
RT-PCR). In each of these categories, we identified
three groups of increasing severity: dengue without
warning signs, dengue with warning signs, and severe
dengue.
Some of the symptoms in the WHO classification were
either missing or poorly described in the consultation
registers, and so we limited our classification to the
following symptoms: nausea/vomiting, pain (headache,
muscle pain, joint pain), rash, tourniquet test, abdom-
inal pain, lethargy/sleepiness, convulsions, and mucous
membrane bleeding. In infants, diarrhea and coughing
were also included. Among dengue cases without
warning signs (presumptive, probable, or confirmed),
we also considered co-existing conditions (pregnancy,
nursing infant, advanced age, diabetes mellitus, HTA,
sickle-cell anemia, and cardiac or renal disease) that
placed them at risk.
Patients’ socio-economic characteristics (access to
water, waste management, possession of durable goods)
were used to construct income quantiles using principal
component analysis (PCA). It was performed using a
tetrachoric correlations matrix (adapted to category var-
iables), and sampling adequacy was assessed using the
overall KMO index (0.79). Income terciles were con-
structed, as the variability of factorial scores did not
allow for isolating quintiles or quartiles. Two binary
outcomes were then constructed based on the dengue
classification. The first outcome was assigned a value of
0 for cases identified without dengue and 1 otherwise,
whereas the second outcome was assigned a value of 1
for probable and confirmed cases of dengue and 0
otherwise. Patients’ sociodemographic and clinical char-
acteristics were compared (bivariate analysis) according
to these two classifications using chi-squared testing.
The second outcome then underwent multiple logistic
regression that included all the variables associated in
bivariate relation to it with a p <0.25 [35]. Based on the
complete model, we successively eliminated non-
significant variables using likelihood ratio tests. The
significance level was set at 0.05, and all data were ana-
lyzed with Stata software, version 13.Healthcare utilization and costs
We calculated expenses for transportation, drugs, la-
boratory tests, as well as total expenses by adding to-
gether the expenses for all services used over the course
of a single dengue episode. This information was ob-
tained during a follow-up visit to the patient within
30 days following diagnosis.
Mobility
Patients’ mobility was assessed during the first day of
consultation and was analyzed based on their reports of
travel undertaken in the 15 days preceding the consult-
ation. These trips were coded to determine their number
and duration, and whether they occurred inside or out-
side of the administrative sector in which the patients
resided.
Entomological survey
Potential Aedes breeding sites were sought and charac-
terized in randomly selected yards and in the yards of
RDT positive subjects; these yards consisted of the peri-
domiciliary area on all sides of each dwelling, generally
bounded by a fence, wall, or other enclosure, and also
included any area within the dwelling that might be used
to store water. Larvae were collected and brought back
to the laboratory of the Institut de Recherche en Sciences
de la Santé (IRSS) in Bobo-Dioulasso to monitor the
emergence of adults. Our aim was to identify the species
and, in the case of Aedes aegypti, to condition them,
either to be able to detect the presence of the virus or to
perform insecticide sensitivity tests (not presented in
this article). As well, adult mosquitoes were collected in
the morning between 8:00 a.m. and 10:00 a.m. with an
electric vacuum cleaner in 20 randomly selected yards in
each neighborhood.
A sample of captured mosquitoes was analyzed for
DENV presence. Total RNA extraction was performed
using Trizol; a DNA copy was obtained using the en-
zyme SuperScrip II and the primer D2 with a final RNA
concentration of 10 ng/uL per sample. The primer D2
was used for the cDNA because it has a high degree of
nucleotide correspondence with the four virus serotypes.
The cDNA product was amplified using nested PCR
with the D1, D2, TS1, TS2, TS3, and TS4, as described
by Lanciotti et al. [33]. These analyses were conducted
at the CIDEIM vector control unit (Cali, Colombia).
Ethical considerations
Informed consent was obtained from each subject.
The study protocol was reviewed and approved by the
National Health Ethics Committee of Burkina Faso
and the Institutional Review Board of the CRCHUM
in Montreal, Canada.
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From a total of 6 957 people consulting at the study
CSPSs, 379 were eligible to participate in the survey
(Fig. 2). All patients who satisfied the inclusion criteria
consented to take part in the study (379/379). Of these,
59.9 % were women (227/379) and 45.4 % (172/379)
were under 15 years of age. The CSPS with the highest rate
of enrolment was that of sector 18, with 23.8 % (90/379),
followed by that of sector 28, with 21.6 % (82/379)
(Table 1). The majority (86.8 %, 329/379) of the patients
had a fever of under five days’ duration, and 8.7 % (33/379)
had positive RDTs for dengue.
Dengue identification
Table 2 shows that, according to the 2009 WHO classifi-
cation, 38.3 % (145/379) of the cases had presumptive,Fig. 2 Enrolment and analysis flowchartprobable, or confirmed dengue, based on clinical signs
and laboratory results.
Of the 379 patients in the sample, 94 (24.8 %) had a
pre-existing medical condition. Among patients classi-
fied as dengue cases without warning signs, there was at
least one co-occurring condition in 36.1 % (n = 13) of
the presumptive cases, 38.9 % (n = 7) of the probable
cases, and 20 % (n = 2) of the confirmed cases. Tables 3
and 4 present the different factors associated with den-
gue infection according to the WHO 2009 guidelines,
including clinical/presumptive assessment, as well as
probable and confirmed classification of the subjects. In
varying the definition of dengue cases (presumptive/
probable/confirmed vs. probable/confirmed), only the
crude association between age group and dengue was
influenced. It became significant (p < 0.01) when




Laboratory investigation N Proportion (%)









IgG positive 7 1.8
IgG and IgM positive 11 2.9
Probable dengue
with warning signs
IgG positive 1 0.3
IgG and IgM positive 5 1.3
Confirmed dengue
without warning signs
PCR positif 7 1.8
AgNS1 and PCR positive 3 0.8
Confirmed dengue with
warning signs
AgNS1 positive 2 0.6
PCR positive 3 0.8
AgNS1 and PCR positive 2 0.6
a According to WHO 2009 guidelines, a presumptive diagnosis is part of the
assessment of the case and is only clinically based (i.e., based on signs
and symptoms)
Table 1 Sociodemographic and clinical characteristics of
patients included in the study
Variables N Percentage
Sex (female) (n = 379) 227 59.9
Age (range 0–61 years) (n = 379)
• Under 5 years 86 22.7
• 5–14 years 86 22.7
• 15–20 years 31 8.2
• 21–30 years 66 17.4
• 31–40 years 58 15.3
• 41–50 years 34 9.0
• Over 50 years 18 4.7
Healthcare center (n = 379)
• CSPS 3 (Dapoya) 42 11.1
• CSPS 8 (Gounghin) 68 17.9
• CSPS 12 (Dapoya) 26 6.9
• CSPS 18 (Pissy) 90 23.8
• CSPS 25 (Somgande) 71 18.7
• CSPS 28 (Dassasgho) 82 21.6
Income tercile (n = 378)
• Lowest 147 38.9
• Middle 120 31.7
• Highest 111 29.4
Water supply source (n = 378)
• Tap water 278 73.5
• Other 100 26.5
Water storage (n = 378)
• No storage 65 17.2
• Covered containers 296 78.3
• Mixed containers 17 4.5
Waste recuperation service (n = 379)
• Yes 243 64.1
• No 136 35.9
Fever durationa (range 0–37 days) (n = 379)
• Up to 5 days 329 86.8
• More than 5 days 50 13.2
Travel abroad (n = 379)
• No 356 93.9
• Yes 23 6.1
a Self-reported by the patient at time of consultation
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of dengue cases (Tables 3 and 4).
Only healthcare center and age group were signifi-
cantly associated with dengue infection in multiple logis-
tic regression (table not presented). Thus, compared
with the CSPS of sector 8 (Gounghin), the OR for sector
25 (Somgande) was 5.7 (CI 95 %: 1.2–27.4). The ORs ofthe other CSPSs were not statistically significant. The
odds of dengue infection for the 15–20 years and over-
50 age groups were 4.0 (CI 95 %: 1.0–15.6) and 7.7 (CI
95 %: 1.6–37.1) times higher, respectively, than for the
under-fives.
RT-PCR serotype identification
Of 60 samples tested by RT-PCR (33 from the positive
tests and 27 from the subsample of negative tests), 15
were positive: nine from positive RDTs and six from the
subsample of negative results (Fig. 3). The serotypes ob-
served, with numbers of cases, were: DENV2 (Dassas-
gho, n = 5; Gounghin, n = 1); DENV3 (Dapoya, n = 1;
Pissy, n = 1; Somgande, n = 4); and DENV4 (Dapoya, n = 1;
Gounghin n = 1; Somgande, n = 1).
Of the 33 subjects with positive RDT results, three were
lost to follow-up; consequently, the analyses of healthcare
use, costs, and entomology, which involved household
visits, were conducted on the remaining 30 subjects.
Healthcare utilization and costs
Table 5 presents the healthcare resources used by sub-
jects with a positive dengue RDT (n = 30) who were
followed up within the 30-day period.
Total spending for a dengue episode (all options com-
bined) ranged from 1 300 to 67 300 FCFA (1US$ = 477
FCFA), with an average of 13 771 FCFA. Drugs
accounted for the largest portion of this total expense,
costing on average 5 163 FCFA inside and 5 398 FCFA
outside the healthcare center consulted. Those in the
lowest income tercile spent on average 8 120 FCFA over
Table 3 Sociodemographic and clinical factors associated with




(n = 145) (%)
p-value
Sex
• Male 152 58 (38.2) 0.974
• Female 227 87 (38.3)
Age group
• Under 5 years 86 31 (36.0) 0.990
• 5–14 years 86 32 (37.2)
• 15–20 years 31 14 (45.2)
• 21–30 years 66 26 (39.4)
• 31–40 years 58 22 (37.9)
• 41–50 years 34 13 (38.2)
• 51 years and over 18 7 (38.9)
Healthcare center
• CSPS 3 (Dapoya) 42 16 (38.1) 0.017
• CSPS 8 (Gounghin) 68 23 (33.8)
• CSPS 12 (Dapoya) 26 12 (46.2)
• CSPS 18 (Pissy) 90 22 (24.4)
• CSPS 25 (Somgande) 71 35 (49.3)
• CSPS 28 (Dassasgho) 82 37 (45.1)
Income tercile (n = 378)
• Lowest 147 53 (36.1) 0.762
• Middle 120 46 (38.3)
• Highest 111 45 (40.5)
Water supply (n = 378)
• Tap water 278 106 (38.1) 0.982
• Other 100 38 (38.0)
Waste management
• Collection service 243 93 (38.3) 0.994
• Other 136 52 (38.2)
Travel abroad
• Yes 23 7 (30.4) 0.426
• No 356 138 (38.8)
Water storage (n = 378)
• No storage 65 24 (36.9) 0.443
• Covered containers 296 111 (37.5)
• Mixed containers 17 9 (52.9)
Fever duration
• Up to 5 days 329 117 (35.6) 0.006
• More than 5 days 50 28 (56)
a Any dengue classification (i.e., presumptive, probable, or confirmed)
Numbers in boldface are p-value statistically significant
Table 4 Sociodemographic and clinical factors associated with








• Male 152 17 (11.2) 0.851
• Female 227 24 (10.6)
Age group (range 0–61 years)
• Under 5 years 86 4 (4.7) 0.001
• 5–14 years 86 3 (3.5)
• 15–20 years 31 6 (19.4)
• 21–30 years 66 8 (12.1)
• 31–40 years 58 9 (15.5)
• 41–50 years 34 5 (14.7)
• 51 years and over 18 6 (33.3)
Healthcare center
• CSPS 3 (Dapoya) 42 3 (7.1) 0.022
• CSPS 8 (Gounghin) 68 2 (2.9)
• CSPS 12 (Dapoya) 26 4 (15.4)
• CSPS 18 (Pissy) 90 6 (6.7)
• CSPS 25 (Somgande) 71 12 (16.9)
• CSPS 28 (Dassasgho) 82 14 (17.1)
Income tercile (n = 378)
• Lowest 147 11 (7.5) 0.195
• Middle 120 14 (11.7)
• Highest 111 16 (14.4)
Water supply (n = 378)
• Tap water 278 33 (11.9) 0.286
• Other 100 8 (8.0)
Waste management
• Collection service 243 27 (11.1) 0.806
• Other 136 14 (10.3)
Travel abroad
• Yes 23 2 (8.7) 0.735
• No 356 39 (11)
Water storage (n = 378)
• No storage 65 8 (12.3) 0.574
• Covered containers 296 30 (10.1)
• Mixed containers 17 3 (17.7)
Fever duration
• Up to 5 days 329 30 (9.1) 0.006
• More than 5 days 50 11 (22)
a Only cases of probable and confirmed dengue
Numbers in boldface are p-value statistically significant
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Fig. 3 RT-PCR products (2 % Agarose gel)
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the middle and highest income terciles spent 17 847
FCFA (range 1 300–67 300) and 15 347 FCFA (range 4
050–51 000), respectively. Of the 30 patients, 66.7 % had
purchased their prescribed drugs from the healthcare
center’s essential generic drugs depot, 83.3 % from a pri-
vate pharmacy, and 10 % from a travelling salesman.
These 30 patients drew upon a variety of sources to pay forTable 5 Patients with positive dengue RDT followed up 30 days
after diagnosis, by characteristics and service use
Variables N Percentage(%)
Diagnosis communicated to the patient (n = 30)
• Dengue 29 96.7
• Malaria 1 3.3
Information provided on infection modalities (n = 30)
• Yes 24 80
• No 6 20
Information provided on healthcare services (n = 30)
• Yes 23 76.7
• No 7 23.3
Status of the illnessa (n = 30)
• Cured 29 96.7
• Still ill 1 3.3
Number of options pursued (different types) (n = 30 patients)
• One option 8 26.7
• Two options 18 60
• Three options 4 13.3
Types of options pursued (n = 58 occurrences)
• CSPS 30 53.6
• Self-medication 18 32.1
• District hospital 1 1.8
• National hospital 1 1.8
• Nursing practice 1 1.8
• Clinic 3 5.4
• Tradi-practitioner 2 3.6
a Self-reported 30 days after diagnosistheir care: salary (50 %), savings (23.3 %), sale of provisions
(3.3 %), help from family and friends (20 %), and tontine
(i.e., a rotating savings and credit association, 3.3 %).
Mobility
Mobility, defined as the number of places visited by the
patient that were not the patient’s residence, was on
average 4.16 for all cases (n = 33), of which the majority
were within the residence sector (2.8 places visited, vs.
1.75 places visited outside the residence sector). Of the
33 cases of positive RDTs, 11 (33.3 %) reported having
travelled outside the capital region, two of whom went
outside the country. Eight cases (24.2 %) had gone out-
side their residence sector and nine cases (27.3 %) had
circulated within their sector in the past 12 h.
Entomological results
In each CSPS’ neighborhood, we surveyed about 20
yards, for a total of 110 randomly chosen yards. The 30
subjects with positive RDT results who were followed up
were distributed in 28 households; their yards were also
examined, for a total of 138 yards surveyed. In those 138
yards, 356 potential breeding sites were identified (aver-
age 2.6 per yard). There were potential Aedes breeding
sites in the yards of 71.4 % of the localized subjects (20/
28). Of the total sites, only one-third were in water (108/
356). Four sites that contained water storage (two in sec-
tor 18, one in sector 25, and one in sector 12) were
found to have Aedes larvae (4/108, or 3.7 %). No positive
breeding site was found in the patients’ yards. The po-
tential breeding sites encountered most often were water
storage containers (terracotta containers or canaris, ce-
ment cisterns, barrels, or buckets) (45.2 %), garbage left
in yards, such as food tins (24.7 %), and tires (21.6 %).
Their distribution differed by sector, suggesting hetero-
geneous behaviors and differences in exposure to Aedes
proliferation depending on area of residence (Fig. 4).
Only Aedes aegypti was identified from the larvae col-
lected and reared to adulthood.
However, the risk of Aedes proliferation in water storage
containers was limited by the fact that 21 % of the
Fig. 4 Distribution (%) of types of Aedes aegypti breeding sites by sector
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that stored water, 38.8 % used closed containers, 24.1 %
did not cover their water containers, and 16.1 % covered
them only partially, exposing them to potential Aedes
colonization. These risky practices were primarily encoun-
tered in sector 25 (Somgande: 58 %), followed by sectors 3
(43 %), 8 (41 %), 12 (41 %), 28 (33 %) and 18 (29 %).
The materials involved in these breeding sites were
primarily plastic (41 %) and terracotta (36.2 %), with
some variations by sector (Fig. 5).
Table 6 presents the results obtained regarding the
adult mosquitoes captured. Most of the capturedFig. 5 Distribution (%) of the materials involved in Aedes aegypti breedingspecimens consisted of Culex (97.9 %). With the excep-
tion of sector 3, where another species, Aedes vexans,
was found, only the species Aedes aegypti was identified.
DENV was not found in any of the Aedes mosquitoes
analyzed using PCR. In the first amplification of the
nested PCR, cryptic bands were observed but failed to
be confirmed in repeat PCR [36].
Discussion
In this study we found that, even though a large number
of patients had positive malaria rapid diagnostic tests,
there was also a proportion of the population withsites by sector








CSPS 3 (Dapoya) 3 (0.2) 41 (2.3) 1 768 (97.6) 1 812
CSPS 8 (Gounghin) 13 (2.1) 0 (0.0) 605 (97.9) 618
CSPS 12 (Dapoya) 3 (1.0) 1 (0.3) 310 (98.7) 314
CSPS 18 (Pissy) 5 (1.6) 4 (1.3) 299 (97.1) 308
CSPS 25
(Somgande)
3 (1.8) 0 (0.0) 160 (98.2) 163
CSPS 28
(Dassasgho)
3 (0.5) 7 (1.1) 648 (98.5) 658
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among the febrile patients consulting at the selected
healthcare facilities in Ouagadougou, there were den-
gue cases from which it was possible to identify for the
first time in the city the simultaneous presence of three
DENV serotypes (DENV2, DENV3, DENV4). Given
these findings, the scientific community, and more im-
portantly the health workers, need to consider dengue
as one possible cause for febrile illness in Burkina
Faso.
We observed positive dengue RDTs in every age
group. Although 45 % of the subjects were under
15 years old, the largest proportion of dengue cases was
seen in patients over age 15 (p = 0.001), which is differ-
ent from patterns observed in Asia but consistent with
previous observations in the region and the country
[14, 25]. Despite the absence of dengue case notifica-
tion by the local surveillance system [37], these findings
suggest a current ongoing transmission of dengue in
the city. The absence of dengue identification and noti-
fication in African countries has been attributed to a
lack of awareness in the population and in healthcare
practitioners and the limited resources available for its
diagnosis, among other causes [16, 18, 25, 38]. How-
ever, it is known that dengue is and has been present in
the African territory and that the absence of infor-
mation could also be related to the clinical form of
presentation in Africans or persons of African ancestry
[38–40].
The role of ethnicity and African ancestry in dengue
has been widely discussed, and a protective role for se-
vere forms has been described [39, 41–43]. In our
study, no severe dengue cases were identified, but
warning signs were present in presumptive, probable,
and confirmed dengue cases. This finding could be due
to a number of situations, such as the presence of
secondary infections [13, 44]. Although it was not pos-
sible to properly distinguish between primary andsecondary infections, due to the presence of positive
IgG results and a previously reported 39 % prevalence
of DENV IgG in a subsample of Ouagadougou’s popu-
lation [23, 25], it is conceivable that dengue has been
present in Ouagadougou. Likewise, the fact that the
majority of dengue cases were adults with pre-existing
medical conditions (DM, HTA, liver or kidney disease,
etc.) may also have played a role in the clinical mani-
festations [41, 43, 44]. The presence of warning signs
and of symptomatology in general could also
be attributed to the presence of DENV3, a serotype
known for its virulence and whose presence has been
reported in other studies [21, 25, 44–46]. On the other
hand, two potential explanations for the absence of se-
vere cases are: 1) the protective role of ethnicity; and
2) the fact that the survey was limited to basic health
centers that do not hospitalize patients but instead
refer all patients presenting with serious symptomatol-
ogy to centers providing a higher level of care or to
hospitals.
Although the three DENV serotypes were co-
circulating in the city, two different serotypes were
observed simultaneously in the CSPSs of sectors 8
(Gounghin) and 25 (Somgande). The fact that the major-
ity of DENV3 positive patients were from Somgande
could be due to the presence of DENV3 in that sector.
Serotype virulence there would lead to people being
more symptomatic and more likely to seek healthcare
attention. However, the mobility of people living in
sector 25 was quite low. The majority of those infected
reported not having travelled within the sector nor out-
side. The low mobility of populations in these sectors is
a factor limiting any spread of disease to the whole city.
Several studies, using modeling, have shown human
mobility to be the primary explanation for disease dissem-
ination in cities in India and Argentina [47, 48].
Even though this study’s findings regarding health ex-
penses and services use are limited because of our small
sample, they nevertheless highlight, once more, the chal-
lenges of healthcare accessibility and the financial bur-
den these can generate [49]. There have been numerous
studies in Burkina Faso on these issues [50], but again,
none have looked specifically at dengue. Such studies
have yet to be conducted in Africa [49], with particular
attention on equity issues. In Cambodia, for example,
studies have revealed the extent to which families
become indebted to cover expenses related to dengue
episodes [51], and the overall financial burden for society
and its economy is enormous [52]. The fact that Burkina
Faso’s health system is still based on user fees means
there is an important financial barrier to healthcare ac-
cess [50]. New dengue epidemics could exacerbate these
impacts for families, especially for the poorest, as was
clearly demonstrated in Cambodia [53].
Table 7 Priorities for public health research and interventions
Research needs:
• Study the seroprevalence and circulation of serotypes.
• Analyze the presence of malaria–dengue co-infection.
• Analyze the health system’s capacity to introduce dengue diagnostic
tools during epidemics.
• Analyze the impacts of human mobility on virus circulation.
• Organize entomological studies on circulation, Aedes presence, etc.
• Organize interdisciplinary and interventional studies on vector
control.
• Study the equity issues raised by dengue.
Public health interventions:
• Mobilize community interventions for vector control.
• Incorporate dengue into the national surveillance system.
• Organize a system to monitor the presence of Aedes.
• Train health professionals in dengue management.
• Inform the population about dengue and the means of controlling it.
• Ensure that malaria RDTs are always available and free of charge in
CSPSs and that dengue RDTs are available during significant epidemics.
• Reinforce the capacities of the national laboratories.
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jority of potential breeding sites found in the sectors
surveyed were made up of water storage containers, in
plastic and terracotta. Even though the city has made
significant advances in its water supply management
since the early 1990s (http://www.wssinfo.org), house-
holds continue to store water. This practice presents a
risk for Aedes proliferation, which appeared to exist
primarily in sector 25, where water containers were
not routinely covered. This result should be confirmed
by entomological surveys of the presence of Aedes lar-
vae in these containers. In Cameroun, in contrast to
what was seen in the rest of Asia, water storage con-
tainers were not preferred breeding sites for Aedes,
which were instead found primarily in abandoned gar-
bage sites and water deposits after rainfalls [54].
Methodological limitations
It is important to note that this study was conducted rap-
idly, without the usual time allotted to preparation, be-
cause of the need to provide Ministry of Health
authorities with rapid data in the context of a new
epidemic in the country [9]. As such, this study was con-
ducted after, or at the end of, a dengue outbreak (i.e., an
unusually high reported number of cases) in the country
after the usual malaria peak and the rainy season. The
window of time available was very brief and there was no
possibility of conducting additional serological tests (e.g.
DENV IgM/IgG ELISA tests) on all the suspected sub-
jects. The absence of specific and confirmatory informa-
tion on DENV antibodies, together with the fever duration
observed, seriously constrained our ability to identify
primary and secondary infections or to rule out false
positives or confirm false negatives that might have re-
sulted from the limited sensitivity and specificity of RDTs.
Moreover, because healthcare attention was focused
on the CSPSs level, it was not possible to have the para-
clinical work-ups (complete blood counts, liver function
tests, etc.) that would have been useful for a complete
clinical profile description and to provide a more accurate
description when applying the 2009 WHO classification
criteria. Also, certain key symptoms (hepatomegaly, ab-
dominal sensitivity to palpation, signs of respiratory dis-
tress, etc.) and other clinical signs (blood pressure, pulse)
normally used to determine the severity of dengue cases
could not be used because they were not covered by the
questionnaire and/or there was excessive missing data
(more than 50 %). All symptoms not reported in the CSPS
register were considered to be absent, even though it was
very probable that some (positive tourniquet test, for ex-
ample) were rarely sought. Even though the results of the
entomological survey were somewhat disappointing, given
the small number of mosquitoes collected and the absence
of productive larval breeding sites, it is highly likely thatthis was due to the period (end of rainy season) in which
the survey was conducted. Interpretation of entomological
information was also limited by the fact that 9.1 % of the
households were not surveyed, and we do not know
whether these were different from the yards surveyed. Al-
though the survey was restricted to only malaria-negative
cases as a way of identifying dengue among the febrile
non-malaria cases and to decrease the possibility of den-
gue false positives among malaria cases in the presence of
limited confirmatory resources, we acknowledge the possi-
bility of a resultant selection bias. Notwithstanding all the
limitations due to the urgency of the need to support
decision-makers, we consider this exploratory study was
helpful in providing information on the presence of den-
gue in Burkina Faso and on the challenges involved in
studying such events.
Conclusion
Dengue continues to be a neglected disease in Africa,
but because of its emergence or re-emergence, it is be-
coming urgent that it be given more serious attention
and that the positive lessons learned from the malaria
journey be applied. This study contributes new and use-
ful knowledge about the presence of dengue virus in
Ouagadougou (Burkina Faso). It should help to direct
more careful attention to clinical management and elicit
more concern from public healthcare actors, in a context
where everyone is calling for increased consideration of
dengue control in Africa [13, 18]. In Table 7, we
summarize the priorities for public health research and
interventions highlighted by this article.
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